Vero Bioscience

What Vero Bioscience does

Vero Bioscience is a privately held, early-stage biotechnology company founded in 2024 and headquartered in San Francisco. According to its company description, it applies proteomic analytics to identify biomarkers and evaluate biological aging across major organ systems, positioning itself within the longevity and health-span diagnostics category. The stated technical thesis is the use of large-scale protein-level data to generate aging-related biomarker signatures, though no specific assays, panels, wet-lab components, or computational pipeline details have been publicly disclosed.

The company operates with a very small team (1–10 employees) and has not yet launched a publicly accessible product or website — verobioscience.com currently displays a verification/loading page with no substantive content. There is no public information on pricing, commercial products, distribution channels, partnerships, customers, or revenue. Its sole publicly disclosed strategic event is an early-stage funding round led by Khosla Ventures on 2025-05-22, though the dollar amount is listed as undisclosed ($0).

The business model is not yet articulated in available sources: it is unclear whether the company intends to monetize via direct-to-consumer testing, B2B biomarker services, pharmaceutical partnerships, or licensed diagnostic IP. Management team, scientific advisors, regulatory pathway, and competitive positioning are all unobservable from current data, making the company a pre-revenue, pre-product entity at the time of this analysis.

Name

Vero Bioscience

Website

https://verobioscience.com

Company type

Private

Founded year

2024

Headcount range

1–10 employees

Short description

Vero Bioscience is a San Francisco-based, early-stage biotech company founded in 2024 that applies proteomic analytics to identify biomarkers and assess biological aging across major organ systems. It is currently pre-revenue with a 1–10 person team and is backed by Khosla Ventures.

Ownership category

akta.pro rank

Product category

Proteomics & Biomarker Analytics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Translational Medicine & Biomarkers (HLAIALAF), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Proteomic analytics
• Biomarker discovery
• Biological aging
• Organ health assessment
• Proteomics research

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Core offering

Vero Bioscience applies proteomic analytics to identify biomarkers and evaluate biological aging across major organ systems. The company translates proteomic data into organ-system-level aging and health insights for research and clinical applications.

Product overview

No product information available. The website (http://verobioscience.com/) displays a verification/loading page ("One moment, please...") with no accessible product, service, or company content.

Differentiator

Problem solved

Functional benefit

Products and services

• Proteomic Biomarker & Biological Aging Analytics

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Nautilus Biotechnology: Nautilus is developing a single-molecule proteomics platform for deep proteome analysis. Vero's proteomic biomarker work competes for the same proteomics-enabled discovery thesis and is likely to use or partner with platforms like Nautilus's.
• Elysium Index: Elysium Health's Index product is a consumer-facing biological age test bundled with the broader Elysium supplement brand. It competes with Vero for the same healthspan-conscious consumer and overlapping scientific messaging around slowing aging.
• TruDiagnostic: TruDiagnostic offers commercial biological age and epigenetic biomarker testing directly to consumers and clinicians, making it the closest head-to-head competitor to Vero's biological age positioning, although Vero differentiates on a proteomic vs. methylation-based platform.
• GlycanAge: GlycanAge provides a direct-to-consumer biological age test based on IgG glycan biomarkers, occupying the same niche of molecular biomarker-driven aging diagnostics that Vero targets with proteomics.
• Seer: Seer is a proteomics platform company whose technology underpins deep, unbiased plasma proteomic profiling. Vero's proteomics-led approach to biomarker discovery is directly comparable in core technology, even though Seer sells into research rather than consumer diagnostics.
• ZOE: ZOE sells consumer-facing biomarker and microbiome testing paired with personalized nutrition, targeting the same healthspan-conscious premium consumer that Vero's biological age test is designed to reach.
• Function Health: Function Health sells comprehensive blood biomarker testing memberships emphasizing early detection and longevity, competing for the same premium consumer segment Vero targets with its aging-focused analytics.
• InsideTracker: InsideTracker offers blood-based biomarker panels with longevity and performance-oriented insights, overlapping with Vero's biomarker analytics value proposition and target customer base of health-optimization consumers.
• Tally Health: Tally Health sells a consumer biological age test (TallyAge) with a strong brand and recurring testing model, directly competing with Vero for premium longevity-testing customers.

Broad incumbents

• Human Longevity Inc. HLI offers whole-genome sequencing combined with deep phenotyping and imaging, providing a broad, well-capitalized incumbent offering in the longevity diagnostics category where Vero is positioning its proteomic panel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vero Bioscience